<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37536948</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-4439</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>BMJ open respiratory research</Title><ISOAbbreviation>BMJ Open Respir Res</ISOAbbreviation></Journal><ArticleTitle>Cross-sectional study evaluating the impact of SARS-CoV-2 variants on Long COVID outcomes in UK hospital survivors.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e001667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjresp-2023-001667</ELocationID><Abstract><AbstractText Label="OBJECTIVES">COVID-19 studies report on hospital admission outcomes across SARS-CoV-2 waves of infection but knowledge of the impact of SARS-CoV-2 variants on the development of Long COVID in hospital survivors is limited. We sought to investigate Long COVID outcomes, aiming to compare outcomes in adult hospitalised survivors with known variants of concern during our first and second UK COVID-19 waves, prior to widespread vaccination.</AbstractText><AbstractText Label="DESIGN">Prospective observational cross-sectional study.</AbstractText><AbstractText Label="SETTING">Secondary care tertiary hospital in the UK.</AbstractText><AbstractText Label="PARTICIPANTS">This study investigated Long COVID in 673 adults with laboratory-positive SARS-CoV-2 infection or clinically suspected COVID-19, 6&#x2009;weeks after hospital discharge. We compared adults with wave 1 (wildtype variant, admitted from February to April 2020) and wave 2 patients (confirmed Alpha variant on viral sequencing (B.1.1.7), admitted from December 2020 to February 2021).</AbstractText><AbstractText Label="OUTCOME MEASURES">Associations of Long COVID presence (one or more of 14 symptoms) and total number of Long COVID symptoms with SARS-CoV-2 variant were analysed using multiple logistic and Poisson regression, respectively.</AbstractText><AbstractText Label="RESULTS">322/400 (wave 1) and 248/273 (wave 2) patients completed follow-up. Predictors of increased total number of Long COVID symptoms included: pre-existing lung disease (adjusted count ratio (aCR)=1.26, 95% CI 1.07, 1.48) and more COVID-19 admission symptoms (aCR=1.07, 95% CI 1.02, 1.12). Weaker associations included increased length of inpatient stay (aCR=1.02, 95% CI 1.00, 1.03) and later review after discharge (aCR=1.00, 95% CI 1.00, 1.01). SARS-CoV-2 variant was not associated with Long COVID presence (OR=0.99, 95% CI 0.24, 4.20) or total number of symptoms (aCR=1.09, 95% CI 0.82, 1.44).</AbstractText><AbstractText Label="CONCLUSIONS">Patients with chronic lung disease or greater COVID-19 admission symptoms have higher Long COVID risk. SARS-CoV-2 variant was not predictive of Long COVID though in wave 2 we identified fewer admission symptoms, improved clinical trajectory and outcomes. Addressing modifiable factors such as length of stay and timepoint of clinical review following discharge may enable clinicians to move from Long COVID risk stratification towards improving its outcome.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saigal</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK rmhaa56@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagoda Niklewicz</LastName><ForeName>Camila</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Sindhu Bhaarrati</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bintalib</LastName><ForeName>Heba M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Amar Jitu</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seligmann</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Alan Stewart</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wey</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abubakar</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahungu</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Virology, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Open Health Care, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Neel Gautam</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brill</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldring</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarvis</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colette</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Global Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogbonnaya</LastName><ForeName>Chibueze</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Child Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipman</LastName><ForeName>Marc C I</ForeName><Initials>MCI</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandal</LastName><ForeName>Swapna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open Respir Res</MedlineTA><NlmUniqueID>101638061</NlmUniqueID><ISSNLinking>2052-4439</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Respiratory Infection</Keyword><Keyword MajorTopicYN="N">Viral infection</Keyword></KeywordList><CoiStatement>Competing interests: JRH, SM and AS report personal fees, and JRH, SM, AS and AJS report non-financial support from pharmaceutical companies that make medicines and medical devices to treat respiratory disease, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37536948</ArticleId><ArticleId IdType="pmc">PMC10401240</ArticleId><ArticleId IdType="doi">10.1136/bmjresp-2023-001667</ArticleId><ArticleId IdType="pii">10/1/e001667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Statista . COVID-19/Coronavirus facts and figures. 2023. Available: https://www.statista.com/page/covid-19-coronavirus [Accessed 05 May 2023].</Citation></Reference><Reference><Citation>Office for National Statistics . Prevalence of ongoing symptoms following Coronavirus (COVID-19) infection in the UK: 30 March 2023. 2023. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023 [Accessed 05 May 2023].</Citation></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. . 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021;76:396&#x2013;8. 10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE guideline [NG188 . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2022. Available: https://www.nice.org.uk/guidance/NG188 [Accessed 14 Mar 2022].</Citation></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, et al. . Prevalence, characteristics, and predictors of long COVID among diagnosed cases of COVID-19. medRxiv [Preprint]. 10.1101/2022.01.04.21268536</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.04.21268536</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Liu Y, Tang X, et al. . The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health 2021;9:775224. 10.3389/fpubh.2021.775224</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.775224</ArticleId><ArticleId IdType="pmc">PMC8669511</ArticleId><ArticleId IdType="pubmed">34917580</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Asai Y, Matsunaga N, et al. . First and second COVID-19 waves in Japan: a comparison of disease severity and characteristics. J Infect 2021;82:84&#x2013;123. 10.1016/j.jinf.2020.10.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.10.033</ArticleId><ArticleId IdType="pmc">PMC7605825</ArticleId><ArticleId IdType="pubmed">33152376</ArticleId></ArticleIdList></Reference><Reference><Citation>Aznar-Gimeno R, Pa&#xf1;o-Pardo JR, Esteban LM, et al. . Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2. Sci Rep 2021;11:18844. 10.1038/s41598-021-98308-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-98308-x</ArticleId><ArticleId IdType="pmc">PMC8458298</ArticleId><ArticleId IdType="pubmed">34552127</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano V, Ganado-Pinilla P, Sanchez-Santos M, et al. . Main differences between the first and second waves of COVID-19 in Madrid, Spain. Int J Infect Dis 2021;105:374&#x2013;6. 10.1016/j.ijid.2021.02.115</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.115</ArticleId><ArticleId IdType="pmc">PMC7934652</ArticleId><ArticleId IdType="pubmed">33684560</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M, Graziani L, Tilli M, et al. . Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses 2022;14:2367. 10.3390/v14112367</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112367</ArticleId><ArticleId IdType="pmc">PMC9698829</ArticleId><ArticleId IdType="pubmed">36366465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, et al. . Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, alpha or Delta SARS-CoV-2 variant. Pathogens 2022;11:725. 10.3390/pathogens11070725</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070725</ArticleId><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022;328:676&#x2013;8. 10.1001/jama.2022.11691</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Notarte KI, Peligro PJ, et al. . Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses 2022;14:2629. 10.3390/v14122629</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE); Royal College of General Practitioners; Healthcare Improvement Scotland SIGN . COVID-19 rapid guideline: managing the long-term effects of COVID-19; National Institute for health and care excellence. London, UK, Available: www.nice.org.uk/guidance/ng188</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet 2022;399:2263&#x2013;4. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Stirrup O, Boshier F, Venturini C, et al. . SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. BMJ Open Respir Res 2021;8:e001029. 10.1136/bmjresp-2021-001029</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2021-001029</ArticleId><ArticleId IdType="pmc">PMC8453594</ArticleId><ArticleId IdType="pubmed">34544733</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation . Living guidance for clinical management of COVID-19. 2021. Available: https://apps.who.int/iris/rest/bitstreams/1394399/retrieve [Accessed 10 Jan 2022].</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, et al. . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693&#x2013;704. 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. . Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020;383:1813&#x2013;26. 10.1056/NEJMoa2007764</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraolo AE, Crispo A, Piezzo M, et al. . The use of tocilizumab in patients with COVID-19: a systematic review, meta-analysis and trial sequential analysis of randomized controlled studies. J Clin Med 2021;10:4935. 10.3390/jcm10214935</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10214935</ArticleId><ArticleId IdType="pmc">PMC8584705</ArticleId><ArticleId IdType="pubmed">34768455</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation . Evidence to recommendations for COVID-19 vaccines: evidence framework. 2020. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-SAGE-Framework-Evidence-2020-1 [Accessed 10 Jan 2022].</Citation></Reference><Reference><Citation>UK Health Security Agency . Research and analysis. variants: distribution of case data, 25 March 2022. 2022. Available: https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-case-data-25-march-2022 [Accessed 25 Mar 2022].</Citation></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, et al. . Long Covid in adults discharged from UK hospitals after COVID-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. Lancet Reg Health Eur 2021;8:100186. 10.1016/j.lanepe.2021.100186</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, de Oliveira MHS, Peligro PJ, et al. . Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med 2022;11:7314. 10.3390/jcm11247314</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Duindam HB, Kessels RPC, van den Borst B, et al. . Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. Brain Behav Immun Health 2022;25:100513. 10.1016/j.bbih.2022.100513</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100513</ArticleId><ArticleId IdType="pmc">PMC9482799</ArticleId><ArticleId IdType="pubmed">36159208</ArticleId></ArticleIdList></Reference><Reference><Citation>Korevaar DA, Aydemir I, Minnema MW, et al. . Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-Dimer testing followed by CTPA. J Thromb Thrombolysis 2021;52:1068&#x2013;73. 10.1007/s11239-021-02508-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02508-1</ArticleId><ArticleId IdType="pmc">PMC8221091</ArticleId><ArticleId IdType="pubmed">34160744</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull CD, Porter BML, Evans SB, et al. . Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respir Res 2021;8:e001044. 10.1136/bmjresp-2021-001044</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2021-001044</ArticleId><ArticleId IdType="pmc">PMC8634283</ArticleId><ArticleId IdType="pubmed">34848495</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022;23:186&#x2013;93. 10.1038/s41590-021-01122-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Corpuz JCG. Adapting to the culture of 'new normal': an emerging response to COVID-19. J Public Health (Oxf) 2021;43:e344&#x2013;5. 10.1093/pubmed/fdab057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdab057</ArticleId><ArticleId IdType="pmc">PMC7989434</ArticleId><ArticleId IdType="pubmed">33683346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: vaccinated people are less likely to get long Covid, review finds. BMJ 2022;376:407. 10.1136/bmj.o407</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o407</ArticleId><ArticleId IdType="pubmed">35172970</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 2022;53:101624. 10.1016/j.eclinm.2022.101624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, et al. . Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J Med Virol 2022;94:3416&#x2013;20. 10.1002/jmv.27689</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>